Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 5/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | GBA1 | P04062 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4043115 | 0.86 | GRIN2B (0.57) | GRIN2BCA1CA2GBA1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL4053518 | 0.84 | GRIN2B (0.56) | GRIN2BCA1CA2GBA1SIGMAR1 | |
| SCHEMBL5354438 | 0.83 | HPGD (0.43) | CA1CA2MEN1ALDH1A1MAPT | |
| SCHEMBL10400096 | 0.83 | IDO1 (0.41) | GRIN2BCA1CA2GBA1MEN1 | |
| SCHEMBL15594563 | 0.83 | GRM7 (0.46) | GRIN2BCA1CA2GBA1IDO1 | |
| SCHEMBL1663167 | 0.81 | ENPP2 (0.48) | ALDH1A1GRM7HRH3 | |
| SCHEMBL4058385 | 0.81 | PSEN1 (0.46) | GRIN2BCA1CA2GBA1NFKB1 | |
| SCHEMBL16718083 | 0.80 | DRD2 (0.35) | GRIN2BGBA1ROCK1NFKB1NFKB2 | |
| SCHEMBL15594558 | 0.78 | KDM4E (0.51) | MEN1KMT2AIDO1 | |
| SCHEMBL15594523 | 0.78 | NPSR1 (0.48) | GBA1MEN1ALDH1A1MAPTALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079559-A1 | S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics | BRIDGE PHARMA, INC. (US) | 2006-04-13 | — | — | US | claimed |
| US-20060079558-A1 | R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics | BRIDGE PHARMA. INC. (US) | 2006-04-13 | — | — | US | claimed |
| WO-2006037047-A2 | THE R-ISOMER OF 2-{2-[N-(2-INDANYL)-N-PHENYLAMINO]ETHYL}PIPERIDINE AND OTHER DERMAL ANESTHETIC AGENTS | BRIDGE PHARMA, INC. (US) | 2006-04-06 | — | — | WO | claimed |
| WO-2006036936-A2 | THE S-ISOMER OF 2-{2-[N-(2-INDANYL)-N-PHENYLAMINO]ETHYL}PIPERIDINE AND OTHER DERMAL ANESTHETIC AGENTS | BRIDGE PHARMA, INC. (US) | 2006-04-06 | — | — | WO | claimed |
| JP-10045687-A | — | — | None | — | — | JP | disclosed |
| EP-3970723-A1 | AMINOINDANE COMPOUNDS FOR USE IN TREATING UROLOGICAL PAIN | Asana BioSciences, LLC (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3363437-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS SOLUTIONS (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3363437-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS SOLUTIONS (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-107540599-B | Aminoindane compounds and their use to treat pain | 阿萨纳生物科技有限责任公司 | 2021-06-04 | — | — | CN | disclosed |
| EP-3363437-A1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | Endo Pharmaceuticals Solutions Inc. (US) | 2018-08-22 | — | — | EP | disclosed |
| EP-2675787-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-2675787-B1 | AMINOINDANE COMPOUNDS AND USE THEREOF IN TREATING PAIN | ENDO PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-1185267-A4 | DERMAL ANESTHETIC AGENTS | BRIDGE PHARMA INC (US) | 2003-09-03 | — | — | EP | disclosed |
| WO-2000076510-A9 | DERMAL ANESTHETIC AGENTS | BRIDGE PHARMA INC (US) | 2002-07-04 | — | — | WO | disclosed |
| US-6413987-B1 | ANALGESICS | BRIDGE PHARMA, INC. | 2002-07-02 | — | — | US | disclosed |
| CN-1355700-A | Skin anesthetic | BRIDGE PHARMA INC (US) | 2002-06-26 | — | — | CN | disclosed |
| EP-1185267-A1 | DERMAL ANESTHETIC AGENTS | Bridge Pharma, Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000076510-A1 | DERMAL ANESTHETIC AGENTS | BRIDGE PHARMA, INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| JP-H1045687-A | PRODUCTION OF 2-INDANYLIDENE-N-PHENYLAMINE AND 2-PHENYLAMINOINDANE | NIPPON STEEL CHEM CO LTD | 1998-02-17 | — | — | JP | disclosed |
| US-3917679-A | Quaternary ammonium salts of N-dialkylaminoalkyl-N-(2-indanyl)anilines | LILLY CO ELI | 1975-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079559-A1 | S-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics | OPRL1, TRPA1, OPRM1 | GRIN2B 283/4885CA1 3342/4885CA2 1709/4885 |
| US-20060079558-A1 | R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics | OPRD1, OPRL1, OPRM1 | GRIN2B 207/4885CA1 3247/4885CA2 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.